Recent trials have demonstrated that the value of programmed death ligand-1 (PD-L1) serves as a predictive factor for survival when ICIs are used whether as monotherapy or in combination therapy of chemo-immunotherapy compared to chemotherapy alone in patients with advanced NSCLC [8,9,10,11,12]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.